|
1
|
Angulo P: Nonalcoholic fatty liver
disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dowman JK, Tomlinson JW and Newsome PN:
Pathogenesis of non-alcoholic fatty liver disease. QJM. 103:71–83.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hassan K, Bhalla V, El Regal ME and
A-Kader HH: Nonalcoholic fatty liver disease: A comprehensive
review of a growing epidemic. World J Gastroenterol.
20:12082–12101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higuera-de la Tijera F and Servín-Caamaño
AI: Pathophysiological mechanisms involved in non-alcoholic
steatohepatitis and novel potential therapeutic targets. World J
Hepatol. 7:1297–1301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hui E, Xu A, Yang Bo H and Lam KS: Obesity
as the common soil of non-alcoholic fatty liver disease and
diabetes: Role of adipokines. J Diabetes Investig. 4:413–425. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fruci B, Giuliano S, Mazza A, Malaguarnera
R and Belfiore A: Nonalcoholic Fatty liver: A possible new target
for type 2 diabetes prevention and treatment. Int J Mol Sci.
14:22933–22966. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leite NC, Villela-Nogueira CA, Cardoso CR
and Salles GF: Non-alcoholic fatty liver disease and diabetes: From
physiopathological interplay to diagnosis and treatment. World J
Gastroenterol. 20:8377–8392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Del Ben M, Polimeni L, Baratta F, Pastori
D, Loffredo L and Angelico F: Modern approach to the clinical
management of non-alcoholic fatty liver disease. World J
Gastroenterol. 20:8341–8350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dixon JB, Bhathal PS, Hughes NR and
O'Brien PE: Nonalcoholic fatty liver disease: Improvement in liver
histological analysis with weight loss. Hepatology. 39:1647–1654.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang HC and Guarente L: SIRT1 and other
sirtuins in metabolism. Trends Endocrinol Metab. 25:138–145. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hardie DG: AMP-activated/SNF1 protein
kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell
Biol. 8:774–785. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hou X, Xu S, Maitland-Toolan KA, Sato K,
Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, et al:
SIRT1 regulates hepatocyte lipid metabolism through activating
AMP-activated protein kinase. J Biol Chem. 283:20015–20026. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Price NL, Gomes AP, Ling AJ, Duarte FV,
Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro
JS, et al: SIRT1 is required for AMPK activation and the beneficial
effects of resveratrol on mitochondrial function. Cell Metab.
15:675–690. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boschmann M, Engeli S, Dobberstein K,
Budziarek P, Strauss A, Boehnke J, Sweep FC, Luft FC, He Y, Foley
JE and Jordan J: Dipeptidyl-peptidase-IV inhibition augments
postprandial lipid mobilization and oxidation in type 2 diabetic
patients. J Clin Endocrinol Metab. 94:846–852. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itou M, Kawaguchi T, Taniguchi E and Sata
M: Dipeptidyl peptidase-4: A key player in chronic liver disease.
World J Gastroenterol. 19:2298–2306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
McIntosh CH, Demuth HU, Pospisilik JA and
Pederson R: Dipeptidyl peptidase IV inhibitors: How do they work as
new antidiabetic agents? Regul Pept. 128:159–165. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Wei R and Hong TP: Potential roles
of glucagon-like peptide-1-based therapies in treating
non-alcoholic fatty liver disease. World J Gastroenterol.
20:9090–9097. 2014.PubMed/NCBI
|
|
18
|
Ideta T, Shirakami Y, Miyazaki T, Kochi T,
Sakai H, Moriwaki H and Shimizu M: The dipeptidyl peptidase-4
inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK
activation in non-alcoholic fatty liver disease model mice. Int J
Mol Sci. 16:29207–29218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blaslov K, Bulum T, Zibar K and Duvnjak L:
Incretin based therapies: A novel treatment approach for
non-alcoholic fatty liver disease. World J Gastroenterol.
20:7356–7365. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the Care and Use of Laboratory Animals. 8th
edition. The National Academies Press; Washington, DC: 2011
|
|
21
|
Xu F, Li Z, Zheng X, Liu H, Liang H, Xu H,
Chen Z, Zeng K and Weng J: SIRT1 mediates the effect of GLP-1
receptor agonist exenatide on ameliorating hepatic steatosis.
Diabetes. 63:3637–3646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan JG: An introduction of strategies for
the management of nonalcoholic fatty liver disease (NAFLD)
recommended by asia pacific working party on NAFLD. Zhonghua Gan
Zang Bing Za Zhi. 15:552–553. 2007.(In Chinese). PubMed/NCBI
|
|
23
|
Chiang YT, Ip W, Shao W, Song ZE, Chernoff
J and Jin T: Activation of cAMP signaling attenuates impaired
hepatic glucose disposal in aged male p21-activated protein
kinase-1 knockout mice. Endocrinology. 155:2122–2132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gault VA, Lennox R and Flatt PR:
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves
recognition memory, oxidative stress and hippocampal neurogenesis
and upregulates key genes involved in cognitive decline. Diabetes
Obes Metab. 17:403–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW,
Lee J, Han JS and Na KY: Dipeptidyl peptidase IV inhibitor
attenuates kidney injury in rat remnant kidney. BMC Nephrol.
14:982013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bell LN, Wang J, Muralidharan S, Chalasani
S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV,
Neuschwander-Tetri BA, Brunt EM, et al: Relationship between
adipose tissue insulin resistance and liver histology in
nonalcoholic steatohepatitis: A pioglitazone versus vitamin E
versus placebo for the treatment of nondiabetic patients with
nonalcoholic steatohepatitis trial follow-up study. Hepatology.
56:1311–1318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takahashi Y and Fukusato T: Histopathology
of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 20:15539–15548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takahashi Y, Soejima Y and Fukusato T:
Animal models of nonalcoholic fatty liver disease/nonalcoholic
steatohepatitis. World J Gastroenterol. 18:2300–2308. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kleiner DE, Brunt EM, Van Natta M, Behling
C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS,
Unalp-Arida A, et al: Design and validation of a histological
scoring system for nonalcoholic fatty liver disease. Hepatology.
41:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Browning JD, Szczepaniak LS, Dobbins R,
Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson
MS, Unalp-Arida A, et al: Prevalence of hepatic steatosis in an
urban population in the United States: Impact of ethnicity.
Hepatology. 40:1387–1395. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loomba R and Sanyal AJ: The global NAFLD
epidemic. Nat Rev Gastroenterol Hepatol. 10:686–690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Wagner LB and Rinella ME: The role of
insulin-sensitizing agents in the treatment of nonalcoholic
steatohepatitis. Therap Adv Gastroenterol. 4:249–263. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Day CP and James OF: Steatohepatitis: A
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Buzzetti E, Pinzani M and Tsochatzis EA:
The multiple-hit pathogenesis of non-alcoholic fatty liver disease
(NAFLD). Metabolism. 65:1038–1048. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park J, Jeon YD, Kim HL, Kim DS, Han YH,
Jung Y, Youn DH, Kang J, Yoon D, Jeong MY, et al: Veratri nigri
rhizoma et radix (Veratrum nigrum L.) and its constituent jervine
prevent adipogenesis via activation of the LKB1-AMPKα-ACC axis in
vivo and in vitro. Evid Based Complement Alternat Med.
2016:86743972016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baran B and Akyüz F: Non-alcoholic fatty
liver disease: What has changed in the treatment since the
beginning? World J Gastroenterol. 20:14219–14229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Machado MV and Cortez-Pinto H:
Non-alcoholic fatty liver disease: What the clinician needs to
know. World J Gastroenterol. 20:12956–12980. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sanyal AJ, Chalasani N, Kowdley KV,
McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE,
Tonascia J, Unalp A, et al: Pioglitazone, vitamin E, or placebo for
nonalcoholic steatohepatitis. N Engl J Med. 362:1675–1685. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ohki T, Isogawa A, Iwamoto M, Ohsugi M,
Yoshida H, Toda N, Tagawa K, Omata M and Koike K: The effectiveness
of liraglutide in nonalcoholic fatty liver disease patients with
type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
ScientificWorldJournal. 2012:4964532012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yilmaz Y, Yonal O, Deyneli O, Celikel CA,
Kalayci C and Duman DG: Effects of sitagliptin in diabetic patients
with nonalcoholic steatohepatitis. Acta Gastroenterol Belg.
75:240–244. 2012.PubMed/NCBI
|
|
41
|
Shirakawa J, Fujii H, Ohnuma K, Sato K,
Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, et al:
Diet-induced adipose tissue inflammation and liver steatosis are
prevented by DPP-4 inhibition in diabetic mice. Diabetes.
60:1246–1257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singh AK: Dipeptidyl peptidase-4
inhibitors: Novel mechanism of actions. Indian J Endocrinol Metab.
18:753–759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee J, Hong SW, Chae SW, Kim DH, Choi JH,
Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, et al: Exendin-4 improves
steatohepatitis by increasing Sirt1 expression in high-fat
diet-induced obese C57BL/6J mice. PLoS One. 7:e313942012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ix JH and Sharma K: Mechanisms linking
obesity, chronic kidney disease, and fatty liver disease: The roles
of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 21:406–412.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Viollet B, Mounier R, Leclerc J, Yazigi A,
Foretz M and Andreelli F: Targeting AMP-activated protein kinase as
a novel therapeutic approach for the treatment of metabolic
disorders. Diabetes Metab. 33:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bungard D, Fuerth BJ, Zeng PY, Faubert B,
Maas NL, Viollet B, Carling D, Thompson CB, Jones RG and Berger SL:
Signaling kinase AMPK activates stress-promoted transcription via
histone H2B phosphorylation. Science. 329:1201–1205. 2010.
View Article : Google Scholar : PubMed/NCBI
|
